ESMO: GSK, iTeos bring some optimism back to TIGIT - Pharmaphorum
GSK and iTeos' anti-TIGIT antibody belrestotug, combined with GSK's PD-1 inhibitor Jemperli, showed higher objective response rates in PD-L1-positive NSCLC patients in the GALAXIES Lung-02 study, though with higher discontinuation rates and treatment-related deaths. The 400mg dose is moving to phase 3 trials.
Reference News
ESMO: GSK, iTeos bring some optimism back to TIGIT - Pharmaphorum
GSK and iTeos' anti-TIGIT antibody belrestotug, combined with GSK's PD-1 inhibitor Jemperli, showed higher objective response rates in PD-L1-positive NSCLC patients in the GALAXIES Lung-02 study, though with higher discontinuation rates and treatment-related deaths. The 400mg dose is moving to phase 3 trials.